Nexalin Technology

Nexalin Technology EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Nexalin Technology (NXL) as of Nov 11, 2026 is 20.34 %. In the previous year, EBIT CAGR (5 Year) was 20.34 % — a change of 0.00% (lower).

EBIT CAGR 5Y

20.34 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Nexalin Technology is 2025 20.34 % . EBIT CAGR (5 Year) of Nexalin Technology was 2024 20.34 % . It decreases by 0.00% lower compared to the previous year.

The Nexalin Technology EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
20.34 USD
Jan 1, 2020
20.34 USD
Jan 1, 2021
20.34 USD
Jan 1, 2022
20.34 USD
Jan 1, 2023
20.34 USD
Jan 1, 2024
20.34 USD
Jan 1, 2025
20.34 USD
The Nexalin Technology EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
20.34 %0.00%
20.34 %0.00%
20.34 %0.00%
20.34 %0.00%
20.34 %0.00%
20.34 %0.00%
20.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

EBIT CAGR (5 Year) of Nexalin Technology is 20.34 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Nexalin Technology

All Key Metrics — Nexalin Technology